James Treanor is an accomplished executive and advisor with extensive experience in the biotechnology and pharmaceutical sectors. Currently serving as an Advisor and SAB member for Karma Biotechnologies and Switch Therapeutics, as well as holding board member and CEO roles at ADRx, Inc., James Treanor has demonstrated leadership in various capacities since 2014. Previous positions include Chief Scientific Officer at Neuron23 and several senior roles at Amgen, where James Treanor was a Scientific Executive Director and Group Leader. Early in the career at Genentech, James Treanor completed a postdoctoral research position in Neuroscience. Academic qualifications include a Ph.D. in Molecular Neurobiology from the University of Bristol and a B.Sc (Hons) in Applied Biology from the University of East London.
Sign up to view 0 direct reports
Get started
This person is not in any teams